Becaplermin gel

Drug Profile

Becaplermin gel

Alternative Names: PGDF-B; Recombinant human platelet-derived growth factor-beta; Regranex; RWJ 60235

Latest Information Update: 28 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson; ZymoGenetics
  • Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
  • Mechanism of Action Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Diabetic foot ulcer
  • Discontinued Pressure ulcer; Varicose ulcer

Most Recent Events

  • 25 Sep 2013 Healthpoint Biotherapeutics is now called Smith & Nephew Biotherapeutics
  • 21 Dec 2012 Healthpoint Biotherapeutics has been acquired by Smith & Nephew
  • 03 Jun 2011 Healthpoint Biotherapeutics acquires becaplermin gel from Systagenix Wound Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top